Back to Forecasting
ATAI Forecast Markets
AtaiBeckley Inc.
7
Active Markets
35%
Avg Probability
All Markets
7 markets
Will ATAI dose the first patient in both BPL-003 Phase 3 pivotal trials by 2026-09-30?
60%
Likely Yes
88% agreement
Sep 30, 2026
IG: 0.72
Will ATAI price a follow-on equity offering of at least $200M at a discount of less than 20% to prior-close by 2026-12-31?
35%
Likely No
88% agreement
Dec 31, 2026
IG: 0.64
Will ATAI's stock price close below $3.00 on any trading day in 2026?
43%
Likely No
86% agreement
Dec 31, 2026
IG: 0.56
Will ATAI disclose an unplanned DSMB safety communication for BPL-003 Phase 3 trials by 2026-12-31?
9%
Likely No
92% agreement
Dec 31, 2026
IG: 0.48
Will ATAI's CEO or CFO disclose open-market net selling of more than $500K via Form 4 in 2026?
38%
Likely No
88% agreement
Dec 31, 2026
IG: 0.40
Will a competing psychedelic Phase 2b or Phase 3 TRD/MDD program (Cybin CYB003, MindMed MM120, or COMPASS COMP360) report a statistically significant primary endpoint hit by 2026-12-31?
40%
Likely No
89% agreement
Dec 31, 2026
IG: 0.40
Will ATAI disclose at least 50% enrollment in one or both BPL-003 Phase 3 pivotal trials by 2026-12-31?
22%
Likely No
90% agreement
Dec 31, 2026
IG: 0.36
Resolution Timeline
Sep 30, 2026
Will ATAI dose the first patient in both BPL-003 Phase 3 pivotal trials by 2026-09-30?Prediction: 60%
Dec 31, 2026
Will ATAI disclose an unplanned DSMB safety communication for BPL-003 Phase 3 trials by 2026-12-31?Prediction: 9%
Dec 31, 2026
Will ATAI's CEO or CFO disclose open-market net selling of more than $500K via Form 4 in 2026?Prediction: 38%
Dec 31, 2026
Will ATAI disclose at least 50% enrollment in one or both BPL-003 Phase 3 pivotal trials by 2026-12-31?Prediction: 22%